<DOC>
	<DOCNO>NCT00182702</DOCNO>
	<brief_summary>This phase II trial study well ixabepilone work treat patient metastatic , recurrent , unresectable kidney cancer . Drugs use chemotherapy , ixabepilone , work different way stop growth tumor cell , either kill cell stop divide</brief_summary>
	<brief_title>Ixabepilone Treating Patients With Metastatic , Recurrent , Unresectable Kidney Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine objective response rate patient metastatic , recurrent , unresectable renal cell carcinoma treat ixabepilone . SECONDARY OBJECTIVES : I . Determine progression-free overall survival rate patient treated drug . II . Determine toxicity drug patient . III . Correlate VHL gene mutation response patient treated drug . IV . Correlate VHL pathway protein expression response patient treated drug . OUTLINE : This multicenter study . Patients receive ixabepilone IV 3 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 9 week disease progression every 3 month 2 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Epothilone B</mesh_term>
	<criteria>Histologically cytologically confirm renal cell carcinoma 1 follow subtypes : Clear cell Papillary , type I II Chromophobe Collecting duct Medullary Metastatic , recurrent , unresectable disease Measurable disease , define ≥ 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No known active brain metastasis require steroid anticonvulsant therapy Patients definitively treat brain metastasis eligible provided steroid anticonvulsant AND show evidence disease progression ≥ 3 month completion definitive therapy Performance status ECOG 02 At least 3 month WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Creatinine ≤ 1.5 time ULN Glomerular filtration rate ≥ 50 mL/min No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No ongoing active infection No HIV positivity No peripheral neuropathy &gt; grade 1 No psychiatric illness social situation would preclude study compliance No history allergic reaction attribute compound similar chemical biological composition study drug No history severe hypersensitivity reaction agent contain Cremophor® EL No active malignancy Curatively treated malignancy allow provide risk recurrent disease time study enrollment &lt; 20 % No uncontrolled illness More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior tubule inhibitor , include , limited , follow : Vinca alkaloid ( e.g. , vinblastine , vincristine , vinorelbine ) Taxanes ( e.g. , docetaxel paclitaxel ) Epothilones No concurrent chemotherapy See Disease Characteristics No concurrent hormonal therapy except steroid adrenal failure hypersensitivity prophylaxis hormone nondisease related condition ( e.g. , insulin diabetes ) More 4 week since prior radiotherapy recover No concurrent palliative radiotherapy No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>